Posted by Michael Wonder on 04 Mar 2024
Two datopotamab deruxtecan applications validated in the EU for patients with advanced non-squamous non-small cell lung cancer or HR positive, HER2 negative breast cancer
4 March 2024 - Parallel applications based on TROPION-Lung01 and TROPION-Breast01 Phase 3 trial results demonstrating Daiichi Sankyo and AstraZeneca’s datopotamab deruxtecan significantly improved progression-free survival versus chemotherapy in two types of cancer.
The EMA has validated two marketing authorisation applications for Daiichi Sankyo and AstraZeneca’s datopotamab deruxtecan in two types of cancer.
